U.S. Markets closed
  • S&P 500

    3,841.94
    +73.47 (+1.95%)
     
  • Dow 30

    31,496.30
    +572.16 (+1.85%)
     
  • Nasdaq

    12,920.15
    +196.68 (+1.55%)
     
  • Russell 2000

    2,192.21
    +45.29 (+2.11%)
     
  • Crude Oil

    66.28
    +2.45 (+3.84%)
     
  • Gold

    1,698.20
    -2.50 (-0.15%)
     
  • Silver

    25.30
    -0.17 (-0.65%)
     
  • EUR/USD

    1.1916
    -0.0063 (-0.5243%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • Vix

    24.66
    -3.91 (-13.69%)
     
  • GBP/USD

    1.3834
    -0.0060 (-0.4344%)
     
  • USD/JPY

    108.3600
    +0.3840 (+0.3556%)
     
  • BTC-USD

    49,405.84
    +626.69 (+1.28%)
     
  • CMC Crypto 200

    982.93
    +39.75 (+4.21%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,864.32
    -65.79 (-0.23%)
     

Recap: Myriad Genetics Q2 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Myriad Genetics (NASDAQ:MYGN) were unchanged in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share decreased 152.17% over the past year to ($0.12), which were in line with the estimate of ($0.12).

Revenue of $154,600,000 declined by 20.76% from the same period last year, which beat the estimate of $150,390,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Myriad Genetics hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Feb 23, 2021

View more earnings on MYGN

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/qfo34i6u

Recent Stock Performance

Company's 52-week high was at $31.59

52-week low: $9.24

Price action over last quarter: Up 69.96%

Company Profile

Myriad Genetics is a molecular diagnostics company, which provides testing services designed to assess an individual's risk of developing a disease. The firm produces myRisk, a 35-gene panel with the capability to identify the elevated risk of developing 8 types of cancer. Other diagnostic products include BRACAnalysisCDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; Vectra DA, which predicts disease progression in rheumatoid arthritis to optimize drug treatment; and Prolaris, which identifies prostate cancer patients that can pursue active surveillance. The firm also offers biomarker discovery and companion diagnostic services to pharmaceutical and biotechnology companies.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.